The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)—A Dutch Breast Cancer Trialists’ Group (BOOG) study.
Ayoub Charehbili
No relevant relationships to disclose
Saskia van de Ven
No relevant relationships to disclose
Gerrit-Jan Liefers
No relevant relationships to disclose
Vincent T. H. B. M. Smit
No relevant relationships to disclose
Hein Putter
No relevant relationships to disclose
Joan Barbara Heijns
No relevant relationships to disclose
Laurens van Warmerdam
No relevant relationships to disclose
Lonneke Kessels
No relevant relationships to disclose
Wouter Dercksen
No relevant relationships to disclose
Manon J. Pepels
No relevant relationships to disclose
Eduard Maartense
No relevant relationships to disclose
Hanneke W. M. Van Laarhoven
No relevant relationships to disclose
Birgit Vriens
No relevant relationships to disclose
Martin N. Wasser
No relevant relationships to disclose
Neveen A.T. Hamdy
No relevant relationships to disclose
Elma Meershoek – Klein Kranenbarg
No relevant relationships to disclose
Elise van Leeuwen-Stok
Research Funding - Amgen; Novartis; Sanofi
Cornelis J. H. Van De Velde
No relevant relationships to disclose
Judith R. Kroep
Research Funding - Amgen; Novartis; Sanofi
J. W. R. Nortier
No relevant relationships to disclose